Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2008
02/21/2008WO2008021781A1 Triazolotriazines as kinase inhibitors
02/21/2008WO2008021745A2 Hepatitis c virus entry inhibitors
02/21/2008WO2008021729A2 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
02/21/2008WO2008021728A2 Treating infections and sequelae thereof with combined dissociated' glucocorticoid receptor agonists and anti-infective agents
02/21/2008WO2008021625A2 Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
02/21/2008WO2008021550A2 Thiol-based agents for reducing toxicities associated with medical procedures employing radiographic contrast agents
02/21/2008WO2008021549A2 Methods and compositions for topoisomerase i modulated tumor suppression
02/21/2008WO2008021545A2 Modulators of muscarinic receptors
02/21/2008WO2008021532A2 Treatment of inflammatory diseases
02/21/2008WO2008021518A2 Crystalline forms of tiagabine hydrochloride and processes for the preparation of amorphous tiagabine hydrochloride
02/21/2008WO2008021486A1 Use of adsborbent carbon microspheres (ast-120) to treat gastroesophogeal reflux disease or symptoms thereof
02/21/2008WO2008021463A2 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
02/21/2008WO2008021439A2 Compositions and methods for treatment of cardiac hypertrophy
02/21/2008WO2008021432A2 Compositions and methods for treatment of conditions affecting the nervous system
02/21/2008WO2008021404A2 Method for treating generalized and focal peripheral neuropathies
02/21/2008WO2008021389A2 Using pi3k and mek modulators in treatments of cancer
02/21/2008WO2008021375A2 Modulators of muscarinic receptors
02/21/2008WO2008021368A2 Compositions and methods for neuroprotection
02/21/2008WO2008021364A2 Triazole compounds that modulate hsp90 activity
02/21/2008WO2008021341A2 Modafinil-based treatment for premature ejaculation
02/21/2008WO2008021338A2 Tricyclic oxazolidone derivatives useful as pr modulators
02/21/2008WO2008021337A1 Oxazinan-2-one derivatives useful as pr modulators
02/21/2008WO2008021309A1 Imidazolidin-2-one derivatives useful as pr modulators
02/21/2008WO2008021296A2 Compositions and methods for the treatment and prophylaxis of alzheimer's disease
02/21/2008WO2008021283A2 Compositions and methods for increasing blood platelet levels in humans
02/21/2008WO2008021242A2 Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
02/21/2008WO2008021237A1 Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
02/21/2008WO2008021213A1 Macrocyclic compounds useful as inhibitors of kinases and hsp90
02/21/2008WO2008021211A2 Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
02/21/2008WO2008021210A2 Methods and compositions for the treatment of neurodegenerative disorders
02/21/2008WO2008021157A1 Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
02/21/2008WO2008021149A2 Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
02/21/2008WO2008021142A2 Process for manufacturing lactose
02/21/2008WO2008021113A2 Transdermal methods and systems for treating alzheimer's disease
02/21/2008WO2008021057A1 Organic nanoparticles and method of preparation thereof
02/21/2008WO2008020962A2 Cholesterol lowering drug combination
02/21/2008WO2008020939A2 Phenylalkyl n-hydroxyureas for combating atherosclerotic plaque
02/21/2008WO2008020902A1 Substituted spirocyclic cgrp receptor antagonists
02/21/2008WO2008020866A1 Ionizable inhibitors of fatty acid amide hydrolase
02/21/2008WO2008020864A2 Imaging correlates of neurogenesis with mri
02/21/2008WO2008020853A1 Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
02/21/2008WO2008020820A2 Pharmaceutical compositions comprising aripiprazole
02/21/2008WO2008020799A1 Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
02/21/2008WO2008020711A1 Quinazoline derivative as phosphodiesterase inhibitor and a process for preparing the same
02/21/2008WO2008020653A1 Use of holliday junction-recognizing protein related to cancer
02/21/2008WO2008020651A1 P2x4 receptor antagonist
02/21/2008WO2008020625A1 Dibenzoylmethane compound and pharmaceutical composition comprising the compound as active ingredient
02/21/2008WO2008020622A1 NOVEL THIENO[2,3-d]PYRIMIDINE COMPOUND
02/21/2008WO2008020617A1 Process for production of brominated acetophenone
02/21/2008WO2008020607A1 Phthalide derivative and salt thereof
02/21/2008WO2008020606A1 Antiangiogenic agent
02/21/2008WO2008020596A2 Treating or preventing cancers over-expressing reg4 or kiaa0101
02/21/2008WO2008020584A1 Stable lyophilized preparation
02/21/2008WO2008020560A1 Antibacterial agent and therapeutic agent for johne's disease comprising the same
02/21/2008WO2008020532A1 Novel crystal of 5-aminolevulinic acid phosphate and process for production thereof
02/21/2008WO2008020495A1 Novel inhibitor
02/21/2008WO2008020491A1 Therapeutic agent for pigmented skin lesion
02/21/2008WO2008020490A1 Artocarpine derivative or artocarpine-like compound, and hair growth/restoration composition, skin-whitening cosmetic composition, pharmaceutical as anti-cancer, antiphlogistic/analgesic, antipyretic or antiallergic agent and pharmaceutical for treatment of pigmented skin lesion each comprising the same
02/21/2008WO2008020489A1 Remedy for inflammatory bowel disease
02/21/2008WO2008020456A2 Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
02/21/2008WO2008020455A2 Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
02/21/2008WO2008020451A2 Nutraceutical compositions and methods of use of safed musli extracts
02/21/2008WO2008020306A2 Isoindole derivatives
02/21/2008WO2008020302A2 Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
02/21/2008WO2008020286A2 Pharmaceutical compositions of duloxetine
02/21/2008WO2008020260A2 Use of siderophores in prevention of vascular diseases, production of siderophores and qualifying siderophore containing meat-products
02/21/2008WO2008020256A2 3,4-dihydrobenzo[1,2,3]thiadiazine-1,1-dioxide derivatives, process for preparation thereof, medicaments containing said derivatives and their use
02/21/2008WO2008020255A1 Benzo[1,2,3]thiadiazine derivatives
02/21/2008WO2008020243A1 Treatment of dna viral infections of the eye
02/21/2008WO2008020222A1 Pyrrole derivatives with antibacterial activity
02/21/2008WO2008020206A2 Fused thiophene derivatives as mek inhibitors
02/21/2008WO2008020203A1 Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
02/21/2008WO2008020180A2 Methods of increasing the sensitivity of cancer cells to dna damage
02/21/2008WO2008020150A1 Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
02/21/2008WO2008020124A1 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin ii receptor antagonists
02/21/2008WO2008020096A1 Pharmaceutical composition with absorption promoters
02/21/2008WO2008020091A1 Pharmaceutical formulation for the treatment of complaints
02/21/2008WO2008020081A1 6-substituted isoquinoline derivatives as rock-1 inhibitors
02/21/2008WO2008020057A1 Aerosol formulation for the inhalation of beta agonists
02/21/2008WO2008020055A1 Novel isoindol derivatives as ep4 receptor agonists
02/21/2008WO2008020045A1 Tetrahydrobenzothiophene derivatives
02/21/2008WO2008020042A1 Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases
02/21/2008WO2008020040A2 2,5-dihydroxybenzene compounds for the treatment of fibrosis
02/21/2008WO2008020039A2 2,5-dihydroxybenzene compounds for treating cancers and hematological dyscrasias
02/21/2008WO2008020037A1 Use of 2,5-dihydroxybenzene derivatives for treating obesity, hirsutism, hypertricosis and viral warts
02/21/2008WO2008020034A1 Use of 2,5-dihydroxybenzene derivatives for the treatment of hemangiomas or hemangioblastomas
02/21/2008WO2008020033A1 Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain
02/21/2008WO2008020032A1 Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
02/21/2008WO2008020031A1 Use of 2,5-dihydroxybenzene derivatives for the treatment of angiogenic diseases
02/21/2008WO2008020030A1 2,5-dihydroxybenzene compounds for the treatment of psoriasis
02/21/2008WO2008020028A1 2,5 dihydroxybenzene compounds for the treatment of rosacea
02/21/2008WO2008020027A2 2,5-dihydroxybenzene compounds for the treatment of skin cancer
02/21/2008WO2008020026A1 Use of 2,5-dihydroxybenzene derivatives for treating dermatitis
02/21/2008WO2008020025A1 Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis
02/21/2008WO2008020024A1 Ntetrahydropyridothiophene derivatives for the treatment of cancer
02/21/2008WO2008020011A1 Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
02/21/2008WO2008019996A2 Formulations of flibanserin and method for manufacturing the same
02/21/2008WO2008019985A1 Method of purifying theaflavins
02/21/2008WO2008019968A1 Non-nucleoside reverse transcriptase inhibitors
02/21/2008WO2008019890A2 Method of modulation of protein phosphorylation-dependent conformational transitions with low molecular weight compounds
1 ... 3368 3369 3370 3371 3372 3373 3374 3375 3376 3377 3378 3379 3380 3381 3382 3383 3384 3385 3386 3387 3388 ... 7860